Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
LTS:0RAR vs ABT, SYK, MDT: Profitability Rank Comparison
For the Medical Devices subindustry, Stratec SE's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stratec SE Profitability Rank vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stratec SE's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Stratec SE's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Stratec SE has the Profitability Rank of 6.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stratec SE (LTS:0RAR) has a Profitability Rank of 6 as of Jun. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Stratec SE and its competitors. This is 25% below median its historical median of 8.00. Over the past decade, Stratec SE's Profitability Rank has ranged from 5.00 to 10.00.
Is Stratec SE's Profitability Rank too high?
Stratec SE's current Profitability Rank of 6 is 25% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, Stratec SE has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stratec SE's Profitability Rank compare to ABT and SYK?
Stratec SE's Profitability Rank of 6 can be compared against companies in the Medical Devices & Instruments industry. Historically, Stratec SE's own Profitability Rank has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Medical Devices & Instruments company?
A good Profitability Rank depends on the Medical Devices & Instruments industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on Stratec SE and its competitors. Stratec SE's current Profitability Rank is 6, which is 25% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stratec SE stock overvalued right now?
Based on GuruFocus' analysis, Stratec SE (LTS:0RAR) is currently considered Modestly Undervalued. The stock's GF Value™ is €28.90, compared to a current price of €24.80 — trading 14.2% below its estimated fair value. The current Profitability Rank is 6, which is 25% below median its 10-year median of 8.00. Stratec SE's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For Stratec SE (LTS:0RAR), the current Profitability Rank is 6 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stratec SE (LTS:0RAR) Overvalued in 2026?
Based on GuruFocus' analysis, Stratec SE stock appears to be undervalued.
The current stock price of €24.80 is trading 14.2% below its estimated GF Value™ of €28.90.
GuruFocus considers Stratec SE to be Modestly Undervalued.
Key valuation signals for LTS:0RAR:
Profitability Rank: 6 (25% below median its 10-year median of 8.00)
GF Value™: €28.90 vs. price of €24.80 (14.2% below fair value)
No single metric tells the full story. See the LTS:0RAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stratec SE designs and manufactures automation solutions for regulated laboratory markets. STRATEC acts as an OEM partner to players in the in-vitro diagnostics and life sciences markets. The Group's product range includes both hardware solutions, software solutions, and related consumables, as well as independently marketed consumables. These products are mostly combined into fully integrated system solutions and often receive market approval together with partners' reagents.
69GF Score
Get the complete analysis for LTS:0RAR
Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAR has been successfully added to your 
